Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy ...Middle East

PR Newswire - News
Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy
Nefecon NDA is currently under Priority Review in China and expected to receive approval in 2H 2023 SHANGHAI, April 5, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and...

Read More Details
Finally We wish PressBee provided you with enough information of ( Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy )

Apple Storegoogle play

Also on site :